NEW YORK (GenomeWeb News) – CombiMatrix will net an additional $1.2 million in funding after its stockholders approved the sale of the company's Series C Preferred Stock, the company said today.

CombiMatrix raised $1.2 million in a first tranche of equity financing in May. The second tranche of that financing was subject to stockholder approval, which was granted at the firm's annual meeting, held on June 27.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.